Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism.

Source:http://linkedlifedata.com/resource/pubmed/id/17100941

Download in:

View as

Triples

General Info

PMID
17100941